The medicine hit its primary endpoint of a decrease in the average daily leg pain intensity as measured by the Numeric Pain ...

Shares of Vertex Pharmaceuticals Inc. VRTX slid 0.46% to $408.76 Friday, on what proved to be an all-around rough trading ...

According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.

This was the stock's fourth consecutive day of gains.

T-Mobile, Toyota Motor, Vertex Pharmaceuticals, BK Technologies and Servotronics are part of the Zacks top Analyst Blog.

We recently compiled a list of the Jim Cramer Discusses 17 Stocks And Blasts Zero Day Options. In this article, we are going ...

Vertex Pharmaceuticals Incorporated (NASDAQ ... However, the company developed its competitive edge with the Trikafta ...

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $408.18, moving +0.72% from the previous trading session. The stock trailed the S&P 500, which registered a daily gain of 1.1%.

Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price hoisted by Scotiabank from $426.00 to $430.00 in a ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Vertex Pharmaceuticals Inc. notched two FDA victories late Friday for its cystic fibrosis medicines, increasing the number of ...